Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3' by M. P. Goetz et al
Ann Oncol. 2024 Dec;35(12):1201-1202.
doi: 10.1016/j.annonc.2024.08.2345.
Epub 2024 Sep 3.
1 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan. Electronic address: [email protected].
2 Department of Health Sciences, University of Genoa, Genova, Italy.
3 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan.